Background
C18 is a covalent inhibitor of glutathione peroxidase 4 (GPX4; IC50 = 120 nM).1 It inhibits the growth of MDA-MB-468, BT-549, and MDA-MB-231 breast cancer cells (IC50s = 10, 75, and 12 nM, respectively). C18 (10 and 20 μM) increases lipid peroxidation and oxidized malondialdede (MDA) levels in MDA-MB-231 cells, an effect that can be prevented by the ferroptosis inhibitor ferrostatin-1 . It decreases mitochondrial volume and induces degradation of mitochondrial crests and outer membranes in MDA-MB-231 cells when used at a concentration of 20 μM. In vivo, C18 (5, 10, or 20 mg/kg) reduces tumor volume and weight, without affecting body weight, in an MDA-MB-231 mouse xenograft model.
动态评分
0.0